Alpine Pharmaceuticals

Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing innovative protein-based immunotherapies for autoimmune and inflammatory diseases. The company utilizes its proprietary Directed Evolution platform to engineer next-generation therapies, including its lead candidate, povetacicept (ALPN-303), a dual antagonist of the BAFF and APRIL pathways. Povetacicept is currently in development for multiple indications, most notably IgA nephropathy (IgAN), where it has shown promising Phase 2 data. In April 2024, the company was acquired by Vertex Pharmaceuticals for approximately $4.9 billion to bolster Vertex's pipeline in kidney diseases and immunology.